Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS

AD Anastasilakis, J Pepe, N Napoli… - The Journal of …, 2022 - academic.oup.com
Context Antiresorptive therapy significantly reduces fracture risk in patients with benign bone
disease and skeletal-related events (SREs) in patients with bone metastases (BM) …

Medication-related osteonecrosis of the jaw: a critical narrative review

AI Lorenzo-Pouso, J Bagán, L Bagán… - Journal of Clinical …, 2021 - mdpi.com
Background: Nearly two decades have passed since a paradoxical reaction in the orofacial
region to some bone modifying agents and other drugs was recognized, namely medication …

Tetrahedral framework nucleic acid promotes the treatment of bisphosphonate-related osteonecrosis of the jaws by promoting angiogenesis and M2 polarization

D Zhao, W Cui, M Liu, J Li, Y Sun, S Shi… - ACS Applied Materials …, 2020 - ACS Publications
Bisphosphonates are often used to treat osteoporosis, malignant bone metastases, and
hypercalcemia. However, it can cause serious adverse reactions, bisphosphonate-related …

Prevalence, incidence rate, and risk factors of medication-related osteonecrosis of the jaw in patients with osteoporosis and cancer: a nationwide population-based …

M Ishimaru, S Ono, K Morita, H Matsui… - Journal of Oral and …, 2022 - Elsevier
Purpose Medication-related osteonecrosis of the jaw (MRONJ) is a rare but severe adverse
event of antiresorptive agents. However, the precise prevalence and factors associated with …

[HTML][HTML] Macrophage miR-149-5p induction is a key driver and therapeutic target for BRONJ

X Shen, W Zhu, P Zhang, Y Fu, J Cheng, L Liu, R Xu… - JCI insight, 2022 - ncbi.nlm.nih.gov
Abstract Bisphosphonate-related (BP-related) osteonecrosis of the jaw (BRONJ) is one of
the severe side effects of administration of BPs, such as zoledronic acid (ZA), which can …

Quality of life in cancer patients with or without medication-related osteonecrosis of the jaw

S de Cassia Tornier, FJ Macedo, LM Sassi… - Supportive Care in …, 2021 - Springer
Purpose Cancer and its therapies can have a significant impact on general and oral health
and, therefore, cause a reduction in patients' quality of life (QoL). The study aimed to …

Does medication-related osteonecrosis of the jaw influence the quality of life of cancer patients?

G Tenore, A Mohsen, AF Rossi, G Palaia, F Rocchetti… - Biomedicines, 2020 - mdpi.com
The aim of this study is to observe the influence of Medication-Related Osteonecrosis of the
Jaw (MRONJ) on the physical and mental conditions of cancer patients using a Quality of …

The use of human amniotic membrane (hAM) as a treatment strategy of medication-related osteonecrosis of the jaw (MRONJ): a systematic review and meta-analysis …

R Sacco, O Akintola, N Sacco, A Acocella… - Medicina, 2023 - mdpi.com
Background and objectives: Although it is very uncommon, medication-induced
osteonecrosis of the jaw (also known as MRONJ) can have serious consequences …

Oral health-related quality of life and mental health impairment in patients affected by medication-related osteonecrosis of the jaws: a case–control pilot study

E Calabria, A Antonelli, S Barone, D Adamo, M Salviati… - Dentistry Journal, 2023 - mdpi.com
In the present case–control study, the impact of medication-related osteonecrosis of the jaws
(MRONJ) on patients' oral health-related quality of life (OHRQoL), overall quality of life …

Is it safe to place implants in patients at risk of MRONJ?

B Owen, H Bradley - Evidence-based dentistry, 2021 - nature.com
Data sources Four electronic databases, namely PubMed, Scopus, Web of Science and the
Cochrane Central Register of Controlled Trials, were searched from their inception to 16 …